ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,213.49
0.51%
Dow Jones
38,675.68
1.18%
Gold vs US Dollar
2,320.09
1.14%
Brent Oil
83.605
0.58%
Bitcoin
64,099.04
0.16%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Adial Pharmaceuticals Inc (ADIL)

  7. Adial Pharmaceuticals Inc (ADIL) News

Adial Pharmaceuticals (ADIL)

Adial Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ADIL
DateTimeSourceHeadlineSymbolCompany
22/04/202413:30GlobeNewswire Inc.Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark OfficeNASDAQ:ADILAdial Pharmaceuticals Inc
10/04/202413:30GlobeNewswire Inc.Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use DisorderNASDAQ:ADILAdial Pharmaceuticals Inc
02/04/202413:30GlobeNewswire Inc.Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business UpdateNASDAQ:ADILAdial Pharmaceuticals Inc
02/03/202400:00GlobeNewswire Inc.Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross ProceedsNASDAQ:ADILAdial Pharmaceuticals Inc
28/02/202414:30GlobeNewswire Inc.Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark OfficeNASDAQ:ADILAdial Pharmaceuticals Inc
14/02/202420:22Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ADILAdial Pharmaceuticals Inc
13/02/202414:15GlobeNewswire Inc.Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark OfficeNASDAQ:ADILAdial Pharmaceuticals Inc
25/01/202421:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ADILAdial Pharmaceuticals Inc
25/01/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ADILAdial Pharmaceuticals Inc
18/01/202421:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADILAdial Pharmaceuticals Inc
18/01/202413:30GlobeNewswire Inc.Adial Announces Appointment of Tony Goodman as Chief Operating OfficerNASDAQ:ADILAdial Pharmaceuticals Inc
16/01/202421:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADILAdial Pharmaceuticals Inc
12/01/202421:51Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ADILAdial Pharmaceuticals Inc
20/12/202314:00GlobeNewswire Inc.Adial Pharmaceuticals Receives Final Reimbursement Payment from AdovateNASDAQ:ADILAdial Pharmaceuticals Inc
12/12/202321:36Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ADILAdial Pharmaceuticals Inc
08/12/202316:08Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ADILAdial Pharmaceuticals Inc
29/11/202321:47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADILAdial Pharmaceuticals Inc
29/11/202321:05GlobeNewswire Inc.Adial Pharmaceuticals Regains Compliance with Nasdaq Listing RequirementNASDAQ:ADILAdial Pharmaceuticals Inc
28/11/202321:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADILAdial Pharmaceuticals Inc
24/11/202314:24Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ADILAdial Pharmaceuticals Inc
20/11/202312:46Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ADILAdial Pharmaceuticals Inc
20/11/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ADILAdial Pharmaceuticals Inc
14/11/202322:02GlobeNewswire Inc.Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:ADILAdial Pharmaceuticals Inc
08/11/202321:05Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:ADILAdial Pharmaceuticals Inc
06/11/202311:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADILAdial Pharmaceuticals Inc
31/10/202312:30GlobeNewswire Inc.Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine ConferenceNASDAQ:ADILAdial Pharmaceuticals Inc
30/10/202321:24Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:ADILAdial Pharmaceuticals Inc
30/10/202321:18Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ADILAdial Pharmaceuticals Inc
30/10/202321:17Edgar (US Regulatory)Form NT 10-Q/A - Notification of inability to timely file Form 10-Q or 10-QSB: [Amend]NASDAQ:ADILAdial Pharmaceuticals Inc
26/10/202322:20Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ADILAdial Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ADIL

Your Recent History

LSE
POS
Plexus
LSE
SBTX
Skinbiotherapeutics
LSE
SRSP
Sirius Petroleum
LSE
BIRD
Blackbird
LSE
AAU
Ariana Resources
LSE
ENET
Ethernity Networks
LSE
SCE
Surface Transforms
LSE
HUM
Hummingbird Resources
LSE
SOLG
Solgold
LSE
INSG
Insig Ai
LSE
OBI
Ondine Biomedical
LSE
AGL
Angle
LSE
GFM
Griffin Mining
LSE
SCLP
Scancell
LSE
LLOY
Lloyds Banking
LSE
CSFS
Cornerstone Fs
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved